AryoGen Pharmed
Tel Aviv, Israel· Est.
Israeli biotech leveraging AI‑enhanced antibody engineering to create novel oncology and immunology therapeutics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
Israeli biotech leveraging AI‑enhanced antibody engineering to create novel oncology and immunology therapeutics.
OncologyImmunology
Technology Platform
A proprietary antibody discovery platform that integrates phage‑display libraries, high‑throughput sequencing, and AI‑driven affinity maturation to generate fully human monoclonal antibodies and bispecific formats.
Opportunities
Leverage AI‑enhanced antibody engineering to accelerate pipeline progression and attract partnership deals with global pharma seeking novel immuno‑oncology candidates.
Risk Factors
Early‑stage development uncertainties, regulatory approvals, and intense competition from established antibody platforms.
Competitive Landscape
Competes with Regeneron, Adimab, and AI‑driven discovery firms; differentiates via a hybrid AI‑phage display platform and strategic Israeli collaborations.